Please login to the form below

Not currently logged in
Email:
Password:

cost-effectiveness

This page shows the latest cost-effectiveness news and features for those working in and with pharma, biotech and healthcare.

Akcea steals march on Alnylam with NICE approval

Akcea steals march on Alnylam with NICE approval

England’s cost effectiveness watchdog says this has addressed the “uncertainties in the company’s economic model” - but Alnylam’s Onpattro is still awaiting the same green light. ... This means the two drugs would both cost approximately £300,

Latest news

  • NICE says no to Novartis’ Kisqali combo in breast cancer NICE says no to Novartis’ Kisqali combo in breast cancer

    Draft guidance from the cost-effectiveness watchdog has concluded CDK 4/6 inhibitor Kisqali (ribociclib) plus fulvestrant should not be offered routinely on the NHS in England for patients with hormone ... Because of the uncertainties in the clinical

  • Biogen’s Spinraza overpriced, says ICER Biogen’s Spinraza overpriced, says ICER

    To reach commonly cited cost-effectiveness thresholds of $100, 000-$150, 000 per Quality-Adjusted Life Year (QALY) gained, Spinraza’s price will need to be slashed by at least ... 76% ($620, 000), evaluating its should-be cost at $72, 000-$130, 000 for

  • NICE nod for Lilly’s breast cancer drug Verzenio via CDF NICE nod for Lilly’s breast cancer drug Verzenio via CDF

    The cost-effectiveness watchdog has opted to make Verzenio (abemaciclib) plus fulvestrant available to around 4, 800 women with hormone receptor (HR) positive, HER2-negative breast cancer which has spread to ... around its cost-effectiveness.”.

  • NICE recommends MSD’s diabetes drug Steglatro NICE recommends MSD’s diabetes drug Steglatro

    In the UK, the treatment is priced at £29.40 for 28 days, a price which NICE points out is the lowest acquisition cost of any SGLT-2 inhibitor. ... England’s cost effectiveness watchdog was also impressed with Steglatro’s efficacy profile, saying

  • NICE green light for Imfinzi in groundbreaking early lung cancer treatment NICE green light for Imfinzi in groundbreaking early lung cancer treatment

    England’s cost effectiveness watchdog’s decision follows the EU marketing approval of Imfinzi (durvalumab) in September last year, and opens up a whole new opportunity to tackle lung cancer at

More from news
Approximately 3 fully matching, plus 525 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 55 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics